In the dynamic world of stock markets, a single analyst’s endorsement can pique interest, but when multiple experts converge on a “buy” recommendation for a particular company, it commands significant attention. This is especially true in the current climate, where geopolitical events in the Middle East have cast a shadow over market valuations, leading to a general downturn. Such periods of correction often present opportune moments to identify undervalued assets with the potential for substantial long-term growth.
With this strategic outlook in mind, we delve into two Australian Securities Exchange (ASX) listed companies that have garnered strong favour among financial analysts. These are businesses that not only exhibit robust financial performance but also possess clear growth trajectories, making them compelling prospects for investors seeking market-beating returns.
Life360 Inc (ASX: 360): Connecting Families and Valuations
Life360 Inc. positions itself as a pivotal player in the family connection and safety sector. Its core mission is to keep individuals closely connected to their loved ones, pets, and important possessions through a suite of innovative services. These offerings include real-time location sharing, detailed safe driver reports, and advanced crash detection technology that can initiate emergency dispatch services.
The company’s reach is truly global, boasting an impressive approximately 95.8 million monthly active users (MAU) spread across more than 180 countries. This vast user base is a testament to the widespread need for its services.
Financial analysts appear to be aligning on the positive prospects for Life360. According to data compiled by CMC Invest, there are currently seven “buy” ratings on the ASX share. The consensus price target stands at $32.80, suggesting a potential upside of around 70% within the next twelve months. This optimism is underpinned by the company’s consistent and impressive growth.
A Closer Look at Life360’s Growth Metrics
Life360’s financial performance in recent periods highlights its compounding growth strategy. In the fourth quarter of FY2025, the company reported a substantial 26% year-over-year increase in revenue, reaching $146 million. Concurrently, its Annualised Monthly Revenue (AMR) saw a significant jump of 30%, climbing to $478 million.
This robust revenue expansion is a direct result of its growing user base. Total MAU increased by 20% year-over-year, with a particularly strong performance in its “paying circles,” which grew by 26% to 2.8 million. This growth is distributed across key markets, with the United States experiencing a 23% surge in paying circles to 2 million, and international markets showing a 32% increase to 0.8 million.
Furthermore, Life360 has effectively leveraged its growing user base by implementing strategic price increases. This has contributed to a 6% year-over-year rise in Average Revenue Per Paying Circle (ARPPC), which reached $139.54. Crucially, this revenue growth is translating into enhanced profitability. In the fourth quarter of FY2025, adjusted operating profit (EBITDA) surged by an impressive 53% to $32.4 million, indicating a healthy improvement in the company’s bottom line and a positive impact on its intrinsic value.
Sigma Healthcare Ltd (ASX: SIG): A Pharmacy Powerhouse
Sigma Healthcare Ltd. is a prominent entity in the Australian healthcare landscape, recognised for its extensive network of franchised pharmacies. The company operates under several well-known brands, including Chemist Warehouse, Amcal, and Discount Drug Stores. Its significant footprint encompasses Australia’s largest retail pharmacy network, with over 880 franchised locations.
Analysts have also expressed a favourable view on Sigma Healthcare. CMC Invest reports that there are currently six “buy” recommendations for the company. The average price target set by these analysts is $3.25, implying a potential appreciation of 24% over the coming year.
The future earnings trajectory of Sigma Healthcare is expected to be predominantly driven by its flagship brand, Chemist Warehouse, owing to its considerable scale and ambitious expansion plans.
Sigma Healthcare’s Financial Performance and Expansion
The company’s recent financial results underscore its strong performance and strategic execution. In the first half of FY2026, Sigma Healthcare achieved a notable 14.9% increase in revenue, reaching $5.5 billion. Its normalised operating profit (EBIT) grew by 18.7% to $582.9 million, while normalised net profit saw a substantial jump of 19.2% to $392 million.
These impressive figures were largely propelled by the stellar performance of its Australian Chemist Warehouse-branded stores, which recorded a sales growth of 17.2%. The expansion of the Chemist Warehouse network remains a key strategic focus. In the first half of FY2026, the company operated 550 Australian Chemist Warehouse stores and 97 international locations, marking an increase from 537 Australian stores and 86 international stores at the close of FY2025. Current international expansion efforts are primarily concentrated in New Zealand and Ireland.
Sigma Healthcare appears to be on a path toward a compelling future, driven by a combination of strong comparable store sales, continuous expansion of its store network both domestically and internationally, and improving profit margins.
According to forecasts on CMC Invest, Sigma Healthcare’s share price is currently valued at 29 times its estimated earnings for FY2028, suggesting a reasonable valuation for its future growth potential.
Disclaimer: This article provides general investment information only and does not constitute financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.















































